HC Wainwright Upgrades Senseonics (NYSE:SENS) to “Buy”

Senseonics (NYSE:SENS) was upgraded by investment analysts at HC Wainwright to a “buy” rating in a research report issued on Monday, Marketbeat Ratings reports. The brokerage presently has a $1.10 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 107.59% from the stock’s current price. HC Wainwright also issued estimates for Senseonics’ Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.06) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.01 EPS.

Other equities analysts have also recently issued reports about the stock. Mizuho began coverage on shares of Senseonics in a report on Thursday, April 10th. They issued an “outperform” rating and a $2.00 target price on the stock. Wall Street Zen upgraded shares of Senseonics to a “sell” rating in a research note on Monday, May 12th.

Senseonics Stock Up 1.2%

SENS opened at $0.53 on Monday. The business’s 50-day simple moving average is $0.61 and its 200-day simple moving average is $0.65. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. Senseonics has a one year low of $0.25 and a one year high of $1.40. The stock has a market capitalization of $346.67 million, a P/E ratio of -4.08 and a beta of 1.05.

Senseonics (NYSE:SENS) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period last year, the business posted ($0.07) EPS. Analysts anticipate that Senseonics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SENS. CTC Alternative Strategies Ltd. acquired a new position in shares of Senseonics during the first quarter worth about $31,000. IFP Advisors Inc increased its position in Senseonics by 120.9% during the 1st quarter. IFP Advisors Inc now owns 47,500 shares of the company’s stock worth $31,000 after purchasing an additional 26,000 shares during the period. Raymond James Financial Inc. acquired a new position in Senseonics during the 4th quarter worth approximately $26,000. Smith Salley Wealth Management acquired a new position in Senseonics during the 1st quarter worth approximately $36,000. Finally, State of Wyoming acquired a new position in Senseonics during the first quarter worth $40,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.